Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/30/2013 |
| Start Date: | May 2012 |
| Contact: | Euodia Jonathan |
| Email: | euodia@stanford.edu |
| Phone: | 650-723-7419 |
This clinical trial studies fluorine F-18 sodium fluoride positron emission tomography
(PET)/computed tomography (CT) in diagnosing bone tumors in patients with cancer. Diagnostic
procedures, such as fluorine F-18 sodium fluoride PET/CT, may help find and diagnose bone
cancer
The objective of the study is to use 18F sodium fluoride (fluorine F-18 sodium fluoride)
PET/CT scanning to detect and characterize lesions in patients who have suspected skeletal
malignancy. We hypothesize that scanning with 18F-NaF (fluorine F-18 sodium fluoride) is
more sensitive for skeletal abnormalities and may better characterize lesions than
conventional imaging.
Inclusion Criteria:
- Patients referred for evaluation of suspected skeletal cancer
- Patients must understand and voluntarily sign an informed consent form after the
contents have been fully explained to them
Exclusion Criteria:
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Healthy volunteers
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
